癌症中的ALK:从功能到治疗向
Claudia Voena1, Chiara Ambrogio2, Fabio Iannelli3
1Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy. claudia.voena@unito.it.
无细胞淋巴瘤激酶 (ALK) 抑制剂对ALK驱动的癌症是有效的,但耐药性发展. 结合ALK疗法和免疫疗法的多方方法可以克服耐药性并改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 无细胞淋巴瘤激酶 (ALK) 是各种癌症中关键的瘤原因驱动因素.
- 表达ALK的瘤最初对ALK抑制剂有反应,但往往会产生耐药性.
研究的目的:
- 审查ALK瘤源信号传导方面的进展.
- 讨论ALK驱动瘤的当前和新型治疗策略.
- 探索结合方法来克服治疗耐药性.
主要方法:
- 关于ALK抑制剂和抵抗机制的当前文献的综述.
- 分析新兴的治疗方式,包括免疫疗法.
- 讨论针对ALK和共存途径的组合策略.
主要成果:
- ALK抑制剂显著影响了ALK+瘤管理,但没有治愈作用.
- 瘤耐药性,复发和转移仍然是一个重大挑战.
- 像ALK特异性免疫疗法这样的新方法显示出有前途.
结论:
- 针对ALK和支持途径的组合策略与免疫疗法一起,对于改善结果至关重要.
- 从ALK+瘤中吸取的教训可以为其他类型的氨酸激酶驱动的癌症的治疗提供信息.
- 需要进一步的研究来开发治愈疗法和预防耐药性.
更多相关视频
10:46A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mitogens and the Cell Cycle
